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Polyphenols and Cognition In Humans:
An Overview of Current Evidence from
Recent Systematic Reviews and
Meta-Analyses
Daniel Joseph Lamport∗ and Claire Michelle Williams∗
School of Psychology and Clinical Language Science, University of Reading, Reading, RG66AL, UK
Abstract.
Background: There is increasing interest in the impact of dietary influences on the brain throughout the lifespan, ranging
from improving cognitive development in children through to attenuating ageing related cognitive decline and reducing risk
of neurodegenerative diseases. Polyphenols, phytochemicals naturally present in a host of fruits, vegetables, tea, cocoa and
other foods, have received particular attention in this regard, and there is now a substantial body of evidence from experimental
and epidemiological studies examining whether their consumption is associated with cognitive benefits.
Objective: The purpose of this overview is to synthesise and evaluate the best available evidence from two sources, namely
meta-analyses and systematic reviews, in order to give an accurate reflection of the current evidence base for an association
between polyphenols and cognitive benefits.
Method: Four meta-analyses and thirteen systematic reviews published between 2017–2020 were included, and were cate-
gorised according to whether they reviewed specific polyphenol-rich foods and classes or all polyphenols. A requirement for
inclusion was assessment of a behavioural cognitive outcome in humans.
Results: A clear and consistent theme emerged that whilst there is support for an association between polyphenol consumption
and cognitive benefits, this conclusion is tentative, and by no means definitive. Considerable methodological heterogeneity
was repeatedly highlighted as problematic such that the current evidence base does not support reliable conclusions relating
to efficacy of specific doses, duration of treatment, or sensitivity in specific populations or certain cognitive domains. The
complexity of multiple interactions between a range of direct and indirect mechanisms of action is discussed.
Conclusions: Further research is required to strengthen the reliability of the evidence base.
Keywords: Polyphenols, cognition, cognitive function, flavonoids, review
INTRODUCTION
Polyphenols are naturally occurring phytochemi-
cals found in a range of foods and drinks such as
fruits, vegetables, tea and cocoa, and the various
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health benefits associated with these foods and drinks
have frequently been accounted for by their polyphe-
nol content. Polyphenols can also be extracted and
consumed as capsulated extracts. The structure and
prevalence of polyphenols has been well defined
elsewhere [see 1–4] and they are commonly cate-
gorised as either flavonoids or non-flavonoids. Over
the past decade there has been a welcome increase in
research exploring the relationship between polyphe-
nol intake in humans and effects on the brain. Broadly,
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the purpose of such research has been to identify
whether polyphenol consumption can produce ben-
eficial outcomes for cognition and to investigate
possible mechanisms of action which may explain
these benefits. Several informative, non-systematic
overviews of cellular mechanisms, rodent models,
clinical trials and epidemiological data have been
published in recent years, which generally argue in
favour of a reliable evidence base for a positive
association between polyphenol consumption and
cognitive benefits [5–10]. This is supported by evi-
dence for mechanisms of action relating to changes in
peripheral and cerebral vascular responses following
polyphenol consumption [11–16]. For example, this
may lead to a biophysiological cascade (both acutely
and chronically) whereby increased cerebral blood
flow (CBF) may lead to increased neuronal activ-
ity, which has been observed with fMRI and other
neuroimaging techniques in humans (see mechanism
considerations). It has been noted though, that whilst
there is strong evidence from in vitro and rodent
research, this has not always translated into clear out-
comes from randomised controlled trials (RCTs) and
other human clinical trials [17]. Meta-analyses and
systematic reviews are generally considered the most
robust approach for evaluating the strength, reliability
and quality of an evidence base. There are now stud-
ies examining the relationship between polyphenols
and cognition to attempt meta-analyses of the avail-
able data, and a multitude of systematic reviews have
been undertaken, in many cases focusing on specific
polyphenol-rich foods. The purpose of this overview
is to gather and evaluate the findings from meta-
analyses and systematic reviews to present the current
status of the relationship between polyphenols and
cognition from the best available evidence. It is of use
to this field to provide a holistic overview of only the
highest quality evidence in light of the large numbers
of studies and reviews that are now available. To avoid
inclusion of multiple systematic reviews which essen-
tially cover the same studies, only meta-analyses and
systematic reviews published between Jan 2017 and
April 2020 were included. A review was considered
systematic if there were explicitly defined inclusion
and exclusion criteria, and only reviews including an
assessment of behavioural outcomes from a cogni-
tive task in humans were included. Therefore, reviews
of purely neuroimaging outcomes, cellular research
and animals models were outside the scope. The pur-
pose was not to undertake a quantitative analysis
of the data, rather to provide a descriptive holistic
overview of the current state of the best available
evidence. The relevance of mechanisms of action
are discussed, and the complex interactions between
these are highlighted. The seventeen reviews included
are summarised in Table 1, and the evaluation of these
is separated into reviews of all polyphenol classes and
sources (n = 4), and reviews of individual polyphenol-
rich foods or classes (n = 13).
HOLISTIC REVIEWS COVERING ALL
POLYPHENOL CLASSES
A number of systematic reviews and meta-analyses
have been published since 2017 which outline the evi-
dence to date for cognitive effects associated with
polyphenol consumption in humans. The majority
of these reviews focus on specific polyphenol-rich
foods (see Table 1), however, there are four which
have incorporated research from a wide range of
polyphenol-rich foods and classes. Three of these
reviews focus on RCTs [11, 18, 19], whilst one is
a broader review of associations between polyphe-
nols and pathologies of Alzheimer’s Disease (AD),
with cognitive function being considered as a pathol-
ogy [20]. The most recent of these [19] included a
meta-analysis in ageing adults >55 years, however,
the utility of this meta-analysis is not wide ranging as
it only included performance on two executive func-
tion tests (Trail Making Test A and B), on account of
the high variability in cognitive tasks between stud-
ies. The respective effect sizes for the TMT A (n = 5
studies) and for TMT B (n = 6 studies) were 0.36
and 0.82, and the authors concluded that polyphenol
supplementation between 6–26 weeks has no sig-
nificant effect on TMT performance, an executive
function task. This is perhaps not surprising given the
small number of studies included. However, within
the same publication, a broader systematic review of
thirteen studies identified that in ageing adults, larger
polyphenol doses (>500 mg/day) may be required
to attenuate cognitive decline over 3–6 months, and
smaller daily doses are only likely to be effective up
to 1 month. In their analysis Ammar et al. [19] also
highlighted the extent to which publications utilise a
single cognitive effect from a wider cognitive bat-
tery to support positive outcomes; of the thirteen
studies six showed enhanced performance on one
cognitive outcome whilst only three showed signif-
icant improvements on two or more outcomes. This
indicates that the literature may be over-interpreting
the strength of findings. The only other meta-analysis
[11] covering a range of polyphenol classes did not




















Summary of meta-analyses and systematic reviews published between 2017–2020 selected for inclusion (alphabetised by polyphenol, then author)
Authors Review Type Polyphenol(s)
or Food(s)





All Healthy ppts > 55 years,
RCTs in a single
population.
Five for TMT A analysis,
six for TMT B analysis.




evidence of bias with
multiple methods
Meta-analysis did not find supportive effects. The
systematic review provided evidence that polyphenols
may benefit cognition in older adults.
Colzinni Syst. Rev. All Observational &
interventions, at least










Not sufficient evidence to confirm that polyphenols have
beneficial effects against AD.




Twenty one, max eight in
any analysis.
– Insufficient evidence to recommended polyphenol
consumption for prevention of cognitive decline.





Evidence for improved cognitive function (or
neuroimaging benefits) when consumed chronically.




Seven – Benefits of anthocyanins are promising with six of seven
studies reporting improvements in either single, or
multiple, cognitive outcomes.
Hein Syst. Rev. Blueberries Healthy or MCI,
interventions only.
Eleven – Benefits for memory and executive function in children,
older adults and adults with mild cognitive impairment.
Travica Syst. Rev. Blueberries Intervention with a
control.
Eleven Low risk of bias
(Cochrane Tool).













Twelve Moderate risk of bias
(Cochrane Tool).
Cognitive benefits ∗sim;50 mg/day epicatechins in healthy
adults aged 18–50. Stronger evidence from studies of





















Authors Review Type Polyphenol(s)
or Food(s)
Key Inclusion Criteria No. Studies Quality and/or Bias
Assessment
Key Findings
Seddon Syst. Rev. Curcumin Double-blind, RCTs,




Five Low risk of bias
(Cochrane Tool).
Benefits found in three of five studies in healthy older
adults. However, insufficient evidence to support
curcumin as a treatment for cognitive decline.
Zhu Meta-analysis Curcumin RCTs, min. duration 4
weeks.
Six Low risk of bias
(Cochrane Tool).
Memory benefits in healthy older adults but no benefit for
AD patients.
Liu Syst. Rev. Ginkgo
Biloba
RCTs. Twenty eight – Doses of 240 mg/day over 24 weeks or more are beneficial
for patients with mild dementia.





Placebo controlled. Eight – Improvements in memory following acute and chronic
administration in patient and healthy populations.









Chronic grape juice consumption (200–500 ml/day)
associated with benefits in older adults experiencing cog
decline.
Mancini Syst. Rev. Green Tea &
associated
extracts.




Twenty one Good quality (DELPHI
list for RCTs and the
Newcastle–Ottawa for
observational studies).
Benefits for memory and attention, but these cannot be
attributed to polyphenols only as effects are linked to the




RCTs. Four Moderate risk of bias
(Jadad method).




RCTs ppts > 18 years,
resveratrol alone or in
combination.
Ten Low risk of bias
(Cochrane Tool). All
outcomes rated at high
or moderate quality
(GRADE tool)
No consistent support for the use of resveratrol
supplementation to improve cognitive performance.
Pooled analysis of n = 3 showed a benefit for recognition
memory
Zaw Syst. Rev. Resveratrol &
Isoflavones
RCTs Twenty three – Eleven studies showed a benefit (or preservation) for
executive function or memory in healthy older adults,
with stronger evidence for resveratrol over isoflavones.
AD = Alzheimer’s Disease; MCI = mild cognitive impairment; Ppts = participants; RCT = randomised controlled trial.
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chronic trials ranging from 4–312 weeks in healthy
adults, which resulted in twenty one studies for inclu-
sion, from which analysis was performed for nine
cognitive outcomes. Consistent with Ammar et al.
[19] there was no effect on Trail Making Test A,
however, there was improvement for Trail Making
Test B which was attributed to two resveratrol stud-
ies, the absence of one of these from Ammar et
al. [19] may partly explain their null effect. Of the
other seven meta-analysed outcomes, only memory
performance (with the Rey Auditory Verbal Learn-
ing Test) was significantly improved by polyphenol
intake, although this analysis only included three
studies. Overall the authors offered a tentative conclu-
sion that polyphenol supplementation might improve
specific cognitive measures. Interestingly, both the
meta-analyses reviewed here are cautious in their
conclusions, however, the findings from a system-
atic review are more positive. Solfrizzi et al. [18]
reviewed eight RCTs published between 2014-2017
on the prevention of late-life cognitive disorders in
healthy older adults (>60 years). The conclusions
were that there was evidence for improved cogni-
tive function (or neuroimaging benefits) for both
non-flavonoid (mainly resveratrol and curcumin) and
flavonoid interventions when consumed chronically.
Comparatively, the systematic review offers stronger
support for cognitive benefits of polyphenol con-
sumption that the meta-analyses, which may well be
a function of the stricter inclusion criteria of the latter.
In light of apparent cognitive benefits observed in
older adults in some chronic trials, it is not surprising
that there is interest in the utility of polyphenols for
reducing risk of AD. However, there is not currently
supportive evidence for benefits translating to these
populations. Colizzi et al. [20] reviewed 24 RCTs and
observational studies which included at least one fac-
tor in the pathology of AD; sixteen of these studies
assessed cognitive function. Interestingly, the authors
summarised that there was not conclusive evidence
for clear beneficial effects of flavonoids or phenolic
acids for cognitive function or other AD pathologies.
Interestingly, their analysis indicated that the major-
ity of studies did show correlations between increased
polyphenol intake and positive cognitive outcomes,
but there were several studies which show both pos-
itive and negative associations, and also studies with
no effects in either direction. Concerningly, a quality
assessment also indicated that the studies of null and
mixed effects were on balance of higher quality than
the studies of positive effects, which may have con-
tributed to the cautious conclusions. Interestingly, the
Text Box 1. Summative interpretation of holistic
reviews [11, 18–20] covering all polyphenol
classes
• The evidence from clinical trials is by no means
conclusive, but there is tentative support for a
relationship between regular polyphenol intake
and cognitive benefits.
• More caution is required when interpreting
findings, especially where a singular effect is
observed amongst a variety of outcomes.
• Evidence is more compelling for benefits
following chronic daily consumption over
several weeks relative to single acute doses. This
may be due to a greater quantity of high quality
chronic studies evaluated in these reviews.
• Older adults appear to be most likely to benefit,
but this can be accounted for by a higher
frequency of studies in older populations rather
than comparisons with other populations.
• There has been very little attempt to systemati-
cally compare polyphenol sources and doses in
individual studies, and it is very difficult to
generate conclusions from study comparisons
due to methodological heterogeneity.
• The reviews recommend larger RCTs with
sample sizes > 100.
• The overall quality of studies evaluated is
moderate to good, and the risk of bias is low.
• A detailed and comprehensive meta-analysis
including all populations would aid confidence
in this field.
overall quality assessment of the studies was mod-
erate (i.e. a sufficient level of quality to consider
outcomes valid) which was echoed by Solfrizzi et al.
[18] who suggested a moderate risk of bias. As might
be expected, one meta-analysis indicated a higher
quality overall [19], likely due to stricter inclusion
criteria, whilst the other [11] did not formally assess
quality or risk of bias. Considering the outcomes of
these four recent holistic systematic reviews there are
some common threads and interpretations which are
described in Text Box 1.
REVIEWS OF SPECIFIC POLYPHENOL-
RICH FOODS OR CLASSES
Between 2017-20 thirteen systematic reviews/
meta-analyses have been published examining the
literature for a specific polyphenol class, or a
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polyphenol-rich food. As summarised in Table 1,
these cover a range of polyphenols, and a maximum
of two reviews exist per polyphenol class or source.
The review of anthocyanin-rich foods [21] is arguably
the broadest, including seven RCTs from apples,
blackcurrants, blueberries, cherries, and grapes, all
in juice or drink form. Similarly to the wider-ranging
reviews described above, the conclusions were ten-
tative; the evidence is promising for a benefit to
cognition, particularly verbal memory, with six of
seven studies showing positive effects on at least
one cognitive outcome measure, but a pooled statis-
tical analysis was not possible due to methodological
variance and weaknesses such as small sample size.
Even solid conclusions relating to efficacy in cer-
tain populations were beyond the reach of the data.
Two systematic reviews focusing on an anthocyanin-
rich food; blueberry [22, 23], also voiced similar
conclusions to the anthocyanin review [21], despite
including a greater number of studies (both eleven,
although the studies included were not identical due
to different inclusion criteria). In both blueberry
reviews methodological heterogeneity was cited as
problematic for systematically evidencing a strong
and consistent picture of benefits, however, promis-
ingly, verbal memory was again cited as a cognitive
domain likely to be most sensitive to blueberry con-
sumption. Interestingly, both of the blueberry reviews
indicated that there is an absence of studies in healthy
young and middle aged adults and the evidence
base relies on studies in children and healthy older
adults (>60 years) or older adults with mild cogni-
tive impairment. Travica et al. [23] also indicated
that there was no consistent pattern of findings in
healthy older adults, largely due to variations in dose,
duration and other methodological factors. The only
other review included of an anthocyanin-rich food
(grapes) [24] indicated more promising conclusions
stating that 200–550 ml/day of grape juice up to dura-
tions of six months was associated with improved
cognitive performance, particularly for older adults
in the early stages of cognitive decline. This bold
conclusion was on the basis of only six RCTs assess-
ing grape juice and cognition, and only three studies
included older adults (the remaining studies in the
review were of wine consumption for which the
evidence showed that light-to-moderate wine; one
to four glasses/day, was generally associated with
improved cognitive performance). Furthermore, the
conclusions relating to dose, population and dura-
tion (see Table 2) are arguably a little overzealous in
light of the small number of studies reviewed [24],
and there was no systematic assessment of bias or
quality. Interestingly, resveratrol was highlighted as
a specific polyphenol which is a possible effector of
the beneficial outcomes of grapes.
Resveratrol was the focus of a systematic review
investigating the effects of phytoestrogen supplemen-
tation on cognition [25], in which eight resveratrol
RCTs (purified or as grape extract) were compared
with another type of phytoestrogens; isoflavones (fif-
teen RCTs). The evidence was inconsistent; less
than half of the studies showed beneficial effects.
However, the authors argued that resveratrol is
emerging as a strong candidate for cognitive enhance-
ment in the older adult population, with benefits
observed for doses between 150–200 mg/day. It
was also suggested that isoflavone supplementation
between 60–116 mg/day up to six months, can ben-
efit cognition. It is notable that isoflavone studies
are often confounded by population bias (typically
postmenopausal women), and interestingly it was
summarised that benefits are most likely in women
who are <10 years postmenopausal. The authors sug-
gested that overall, the evidence was stronger for
resveratrol although no direct statistical comparisons
were made between isoflavone and resveratrol out-
comes. There was no assessment of study bias or
quality, and given the overall weighting to a greater
number of non-significant studies, the conclusions
appear optimistic.
This optimism is not reflected in the findings
from two recent meta-analyses of resveratrol sup-
plements for cognitive outcomes; one included four
studies [26] and another more wide-ranging anal-
ysis of ten studies [27]. Perhaps unsurprisingly, in
light of the small number of studies, the former [26]
concluded that there was no evidence for benefits
of resveratrol for cognitive performance, although
the analysis was focused on verbal memory outcome
measures. As cited in previous reviews, methodolog-
ical heterogeneity was a problem, and subsequently
any pooled analyses contained data from no more
than two trials. The larger meta-analysis [27] also
included a focus on memory outcomes, and a pooled
analysis indicated that resveratrol consumption can
improve memory, specifically delayed recognition,
although the effect size was small (a standardized
mean difference, SMD, of 0.39) and only three studies
contributed to this analysis. Two further pooled anal-
ysis for processing speed and number facility failed to
find any effect of resveratrol, and five of the included
ten studies did not find effects on cognition. More-
over, a GRADE tool (Grading of Recommendations,
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Table 2
For reviews of individual polyphenol-rich foods or specific sub-classes, a summary of the evidence base available for efficacy in specific
populations, doses, duration of intervention, and cognitive domains. Insufficient data indicates that there was not available data to provide a
systematic comparison between groups of the relevant variable (alphabetised by author)
Author & Polyphenol Population sensitivity Dose sensitivity Cognitive domain
sensitivity
Duration sensitivity
Barrera-Rayes: Cocoa Younger adults show
more benefits than older
adults.
500–750 mg/day Insufficient data Insufficient data
Farzei: Resveratrol Insufficient data Insufficient data Only memory assessed –
no effects
Insufficient data
Hein: Blueberries Only children and > 60
years assessed.






studies in children and
chronic in old.
Kent: Anthocyanins Insufficient data Insufficient data Verbal memory and
learning.
Insufficient data
Lui: Gingko biloba Patients with mild
dementia.
240 mg/day Insufficient data Chronic doses of
minimum 24 weeks.
Mancini: Green Tea &
extracts
Insufficient data Insufficient data Memory and attention. Insufficient data
Marx: Resveratrol Insufficient data Insufficient data Delayed recognition. Long term trials more
likely to show benefits.
Reay: Ginkgo Biloba &
Ginseng
Insufficient data Insufficient data Memory (specifically
secondary memory).
Insufficient data
Restani: Grapes Older adults in the early
stages of cognitive
decline.




Chronic doses up to 6
months.
Seddon: Curcumin Insufficient data Insufficient data Insufficient data Insufficient data
Travica: Blueberries May benefit older adults. Insufficient data Insufficient data Insufficient data
Zaw: Isoflavone Females<10 years
postmenopausal.
60–116 mg/day Insufficient data Chronic doses between 12
weeks and 6 months.
Zaw: Resveratrol Older adults. 150–200 mg/day Insufficient data Chronic doses of
minimum 14 weeks.
Zhu: Curcumin Older adults. Insufficient data Memory. Insufficient data
Assessment, Development, and Evaluation) found
moderate to high confidence that resveratrol supple-
mentation has no significant effect on most outcomes
in the general population.
Therefore, these meta-analyses [26, 27] do not
provide compelling evidence for beneficial effects
of resveratrol on cognition, and there is certainly
not a strong enough evidence base to make con-
clusions regarding dose, population or duration of
intervention. This is unsurprising given the small
number of studies included in the pooled analyses,
and once again, methodological heterogeneity is cited
as barrier to reliable summative conclusions. The het-
erogeneity limitation was also highlighted by the only
other meta-analysis included here (curcumin [28]),
so much so that a sensitivity analysis was not pos-
sible, and the overall quality of the evidence was
cited as low. Nevertheless, pooled-analysis of three
studies in older adults showed a benefit of curcumin
for memory (SMD = 0.33), matching some of the
aforementioned reviews of other polyphenol sources.
However, in two studies of AD patients, the data
showed a non-significant trend for curcumin to per-
form worse than placebo (SMD 0.9) on a global
cognitive measure (Mini Mental State Examination).
The evidence for curcumin was also evaluated in
a systematic review of fives studies [29]. Three of
the five studies found improvement in performance
following curcumin, however the conclusions state
that there is insufficient evidence to support cur-
cumin supplementation as an effective means of both
preventing and treating dementia and symptoms of
cognitive decline. Methodological heterogeneity and
small sample sizes were the primary limitations ham-
pering generalisability; this is clearly a consistent
theme of the evidence reviewed here.
Reliable, generalizable conclusions are likely more
attainable from reviews of a larger pool of stud-
ies. A systematic review of Gingko Biloba leaf
extract [30] including twenty eight studies in healthy
adults and AD patients reported positive outcomes;
daily doses of 240 m/day were summarised to bene-
fit patients with mild AD symptoms, despite eleven
studies failing to report an effect. Nevertheless, it
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was evident that these negative studies were largely
in younger healthy adults, and included a greater
frequency of single dose studies, and chronic tri-
als of shorter duration. Therefore, these conclusions
offer a sensible degree of reliability. However, even
with the larger number of studies included, a sys-
tematic analysis of which cognitive domains may be
most affected was not achievable, and risk of bias
or study quality were not evaluated. Some positive
outcomes were also reported from a smaller system-
atic review [31] which considered eight studies of a
commercially available supplement which contains
Gingko combined with Ginseng, both of which are
considered polyphenol-rich traditional herbal supple-
ments. A discursive analysis of the cognitive domains
affected and duration of treatment was undertaken,
with conclusions being that memory can be improved
in healthy and patient populations as soon as one
hour post consumption, with repeated chronic dosing
also benefiting memory. However, there was limited
data directly comparing doses, duration or popula-
tions under similar methodological conditions, and it
was interesting to note that five of the eight studies
were from the same research group. An advantage
of this is that it allows consistency in the cognitive
assessment, and may explain why there is evidence
for a memory effect from a comparatively small
number of studies, whilst a disadvantage is that
this evidence base lacks replicability across research
groups, simply on account of the small number
of studies. A systematic analysis of bias or qual-
ity was not undertaken, although it was concluded
that the methodologies were robust and well con-
trolled. Interestingly, two studies reported that the
synergy of Gingko and Ginseng was more efficacious
than the individual constituents combined; synergis-
tic polyphenol effects have received little attention in
the reviews presented here, most likely as there is not
currently an evidence base to draw data from.
Conversely, cocoa is a polyphenol source which
has attracted relatively widespread investigation of
potential cognitive benefits. A systematic review of
twelve clinical trials presented a detailed overview
of dose, population, treatment duration and cognitive
domains affected [32]. The evidence was perhaps the
most supportive seen throughout this review; eight
studies reported a benefit for a behavioural outcome,
and the conclusions stated that effects on cognitive
function were reliably observed after consumption
of 50 mg/day of epicatechin in adults aged 18–50
years. Interestingly it was reported that effect sizes
were higher for daily doses of between 500–750 mg
compared to 750 mg, and effects were more con-
sistently observed in younger adults compared to
older adults. However, there was insufficient compar-
ative data for conclusions on treatment, duration and
whether certain cognitive domains are more sensitive,
rather effects were generally reported for memory and
executive function. Concerns were highlighted with
respect to risk of bias, with five studies judged as
poor quality and only two as good quality using the
Cochrane Tool. This raises doubt on the reliability
of the positive effects of cocoa, and emphasises that
further good quality research is required. Encourag-
ingly, the studies of higher quality and lowest risk of
bias provided the strongest effects of cocoa associated
cognitive benefits, particularly studies which utilised
a placebo matched for potentially confounding com-
pounds such as caffeine and theobromine. The effect
of confounding components is also problematic in
the green tea polyphenol and cognition literature. For
example, a systematic review of twenty one stud-
ies of green tea and associated extracts reported that
epidemiological cohort studies support cumulative
cognitive benefits from habitual intake of 100 ml/day,
and the data from sixteen clinical trials suggest ben-
efits for memory and attention [33]. On the face of
it, this appears positive, however, it was concluded
that the cognitive improvements are strongly linked to
the presence of both caffeine and L-theanine, and the
benefits cannot be attributed to a singular component
such as polyphenols. Some evidence of synergistic
benefits was reported, which echoes findings from the
Ginkgo/Ginseng review [31]. However, once again,
significant methodological heterogeneity was cited as
hampering conclusions relating to dose, population
and duration of effects.
In summary, a number of informative systematic
reviews and meta-analyses have been published in
recent years examine individual polyphenol classes or
polyphenol-rich foods. Data from the meta-analyses
appear to be less convincing than findings from sys-
tematic reviews, which may reflect stricter inclusion
criteria and lower power on account of the difficul-
ties in combining data from heterogeneous studies.
It appears that the current state of the literature base
is not sufficiently advanced to support meaningful
systematic analysis of specific polyphenol classes, or
polyphenol-rich foods (see Table 2). Encouragingly,
the three meta-analyses discussed here report a low
risk of bias overall, which indicates that the studies
included are of strong methodological design. Only
four systematic reviews considered risk of bias (or
quality) with a standardised tool (e.g. Cochrane Tool),
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Text Box 2. Summative interpretation of reviews
[21–33] covering individual polyphenol-rich
foods and classes
• All ten systematic reviews indicated some
support for positive effects of the reviewed
polyphenol on cognition. However, most reviews
expressed caution, showing that benefits were
not consistent across all studies.
• Two of three meta-analyses reported that there
was no consistent evidence for a benefit of the
reviewed polyphenol on cognition.
• Verbal memory is consistently appearing as a
cognitive domain showing greatest sensitivity to
polyphenols, however, this is strongly associated
with greater frequency of assessment relative to
other domains, which may reflect ease of
assessing memory.
• Older adult populations have received more
attention and there are very few instances of
direct population comparisons.
• Methodological heterogeneity was highlighted
as problematic for surmising consistent and
reliable evidence regarding dose, duration,
population, and cognitive domain.
• The larger systematic reviews tended to argue
for a stronger evidence base overall,
nevertheless, these still contain numerous studies
of non-significant effects.
• Dose-response studies are required assessing
multiple doses in the same population acutely
and chronically.
• Of those that reviewed quality, most reported
moderate to high quality, and a low risk of bias.
but positively, these largely indicated low risk of bias.
However, the cocoa review [32] did express moder-
ate concerns relating to matched controls in some
studies. Interestingly, the picture from the reviews of
individual polyphenol classes is slightly more posi-
tive regarding cognitive outcomes than the reviews
of all polyphenol classes (see section 2), however,
as summarised in Text Box 2, the evidence for a
positive relationship between polyphenols and cog-
nitive benefits is perhaps not as strong as might be
anticipated.
MECHANISTIC CONSIDERATIONS
In order to fully understand the relationship be-
tween polyphenol consumption and cognitive
function it is important to have an understanding of
the mechanisms of action which may account for
behavioural effects. There has been much exploration
of the role of increased CBF following polyphenol
consumption [34–36], which may lead to increased
neuronal activity as assessed by fMRI and other
neuroimaging techniques [37]. This cerebral vascu-
lar mechanism is supported by evidence showing
an improved peripheral vascular response such as
reduced blood pressure and increased flow mediated
dilation following polyphenol consumption [11–16].
This vascular responsivity mechanism is under-
pinned by in-vitro and animal data demonstrating
that polyphenols can affect multiple cellular path-
ways thought to be responsible for vascular changes
[11, 12, 38, 39]. It logical to consider that short term
peripheral and cerebral vascular changes over sev-
eral hours may account for acute behavioural effects
of polyphenols. However, chronic activation of these
pathways may also support long term behavioural
benefits if the cerebrovascular mechanistic process
becomes more efficient following repeated improve-
ment over time. It is difficult, though, to attain
evidence directly supporting these processes as we
are unable to directly examine the cellular pathways
in a human brain during a cognitive task. Rather we
are able to observe proxies for neural activation such
as improved CBF with arterial spin labelling (ASL),
and changes in the ratio of oxygenated to deoxy-
genated blood with fMRI. Other techniques such as
electroencephalography (EEG) can offer better tem-
poral resolution [40] however, in summary we cannot
directly observed the pathways between polyphe-
nol intake, improved blood flow, neuronal activation
and improved behavioural performance in humans.
Nevertheless, in-vitro cellular work in combination
with rodent studies provides good evidence for a
cascade a mechanisms which associate polyphenols
with changes in neuronal morphology and synaptic
plasticity [41–43] and it is plausible that these mech-
anisms of action may account for chronic behavioural
benefits in humans.
Studies targeting specific mechanisms of action
and associated cognitive effects are important and
should continue. However, it is becoming increas-
ingly apparent that there are a host of complex
pathways and mechanisms which are interacting in
their contribution to behavioural outcomes. In any
study (acute, chronic, or epidemiological) the assess-
ment of cognitive performance is not undertaken
outside of the context of everyday life. Participants
bring their own influences such as habitual diet,
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subjective mood state, underlying cognitive abilities,
and a host of metabolic and physiological charac-
teristics such as the gut microbiota, and it is likely
that this variance is contributing to the inconsis-
tent behavioural data highlighted in this overview.
Attempts can be made to control for some of these
characteristics in order to identify specific associa-
tions between cognitive effects and mechanisms of
action, with the compromise being that the findings
from such studies can only be applied to certain pop-
ulations and experimental conditions. By gaining a
holistic understanding of the wider influences, and the
complex nature in which these factors interact, future
work may be able to more accurately understand and
hypothesis when and how polyphenol intake is likely
to benefit cognitive function.
Considering these influences in a little more detail,
there is now reasonable evidence for several variables
potentially moderating or mediating the relation-
ship between polyphenols and cognition. The gut
microbiota can be broadly considered as the gate-
way for all effects since all ingested polyphenols
will pass into and through the gut (at least partially)
before reaching the blood stream through which they
are distributed throughout the body. Therefore, the
gut environment and gut microbiota has an impor-
tant influence, and there is evidence of a complex
bidirectional relationship between gut microbiota,
polyphenols and cognition [44–46]. Given that there
is significant divergence between individuals in their
gut microbiota, it follows that the metabolic fate of
polyphenols is not consistent, and thus this indi-
vidual variation is likely to contribute to variance
in cognitive outcomes following polyphenol intake
[46–49]. Moreover, meta-analyses show that the
bioavailability of polyphenols is an important aspect
in determining likelihood of cognitive outcomes with
one review stating that > 9% bioavailability is needed
to improve brain health in older adults [19]. Other fac-
tors such as the food matrix are also thought to impact
upon the subsequent bioavailability of polyphenols
and thus outcomes may vary depending on whether
polyphenols are consumed as an extract or whole food
[20, 50, 51]. Habitual diet is also likely to shape the
state of the gut microbiota, indeed dietary factors have
been suggested to account for a significant percent-
age of the microbiota variance between individuals
[52, 52]. Moreover, a greater intake of polyphenol-
rich foods has been associated with greater microbial
diversity and enhanced growth of bacterial species
associated with health benefits [54–57]. However,
it is currently unclear whether cognitive benefits
following polyphenol consumption are more likely
to be observed in frequent habitual polyphenol con-
sumers (in whom the gut environment is likely to
be more efficient at metabolising polyphenols) or
in habitually low polyphenol consumers, who may
receive an immediate benefit on account of an absence
of previous intake. Alternatively, low habitual con-
sumers may not have a gut environment which can
efficiently metabolise polyphenols, and thus cogni-
tive benefits may be limited. Aside from polyphenols,
there are a host of hypothesised bidirectional path-
ways between the gut and the brain [58, 59] and there
is potential for polyphenols to interact with multiple
aspects of this gut-brain axis [44, 46].
Another physiological variable which may medi-
ate/moderate the relationship between polyphenols
and cognition is insulin sensitivity. It is well estab-
lished that type 2 diabetes (T2DM) and impairments
in insulin sensitivity negatively impact cognitive
function [60, 61]; this is of interest here since
polyphenols are known to improve insulin sensitiv-
ity and reduce risk of T2DM [62, 63]. Therefore,
polyphenols may be contributing to cognitive benefits
via mechanisms associated with insulin sensitivity
[42, 64–66]. For example, the brain has a high degree
of insulin receptors [67, 68], and rodent models
show that increased insulin resistance in the brain
can impair cognition [69]. Furthermore, poor insulin
sensitivity and T2DM is associated with endothe-
lial dysfunction in the blood brain barrier [70],
which could be a cerebrovascular mechanism shared
between T2DM and polyphenols [64, 66, 71]. For
example, resveratrol can reduce blood brain bar-
rier permeability in rodents which has been shown
to be accompanied by inhibited hippocampal neu-
rodegeneration [72]. Furthermore, acute and chronic
cognitive improvements following polyphenol con-
sumption have been associated with improvements
in insulin sensitivity [73–75]. To add a further layer
of complexity, the gut microbiota is known to impact
upon the regulation of systemic insulin sensitivity via
functional metabolites [76, 77]. Therefore, there is
likely to be a complex interactive pathway between
polyphenols, the gut microbiota, insulin sensitivity
and cognition, and this requires exploration. T2DM
is also characterised by low mood and increased
incidence of depression which further complicates
potential mechanisms of action since low mood is
also associated with cognitive impairments [78].
This pathway has relevance for polyphenol-cognition
research as there is now data from epidemiological
studies [13, 79] and clinical trials [80–82] showing
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Table 3
– Hypothetical methods for defining a cognitive benefit associated with polyphenol consumption
Definition Considerations
An improvement over time relative to baseline. If a placebo also shows a similar profile this implies practice effects.
Better performance at any given time point relative to a
placebo.
Can be misleading if the baseline is not the same for placebo and polyphenol.
A steeper improvement over time relative to a placebo. Important to check raw scores, the polyphenol condition could have lower
performance per se.
Attenuation of a decline over time relative to a placebo. Typically demonstrated by no change in performance for the polyphenol but a
decline over time for a placebo.
Slower rate of decline relative to a placebo. A decline may be observed in polyphenol and placebo conditions. More likely
in ageing or impaired populations.
Reduced risk of developing a cognitive impairment
relative to a placebo.
Common in epidemiological studies, assessing cases of neurodegenerative
disease over time.
Correlation between increased polyphenol intake and
better cognitive performance.
Important to check how cognitive performance is defined.
that polyphenols can reduce risk of depression and
negative mood and also improve positive mood, both
acutely and chronically. Several supporting mecha-
nisms have been proposed [83] involving regulation
of neurotransmitters via changes in short chain fatty
acids and tryptophan metabolites, and various other
molecular cascades potentially affecting neuroin-
flammation and synaptic plasticity, all of which are
intrinsically linked to the gut microbial environment.
This highlights an emerging complex system where
polyphenols may be affecting cognition via multi-
ple pathways associated with changes in subjective
mood, which could occur over both acute and chronic
timeframes. However, this remains speculative, and
it is important to point out that a systematic evalua-
tion of the impact of polyphenols on mood, and the
interaction with cognition requires investigation. In
summary, polyphenols have a multitude of bidirec-
tional actions in the body and appear to have influence
on various mechanisms which affect cognitive func-
tion independently of polyphenol intake. Therefore, it
is important that future research considers both direct
(e.g. CBF and neurogenesis) and indirect (e.g. insulin
sensitivity, subjective mood, and gut health) mech-
anisms of action when investigating the effects of
polyphenols on cognitive performance in humans.
WHAT DO WE MEAN BY A COGNITIVE
BENEFIT?
A topic seldom discussed in this literature is the
variety of ways in which a behavioural cognitive ben-
efit is defined. This has undoubtedly contributed to
the difficulties in comparing cognitive effects across
populations. It is reasonable to hypothesise that cog-
nitive benefits associated with polyphenols (and other
nutritional influences) will manifest in different ways
throughout the lifespan; children may experience
and increase in the speed and trajectory of cognitive
development, young healthy adults at the peak of their
cognitive lifespan may seek to maximise cognitive
potential, whilst older adults may look to attenu-
ate the trajectory of cognitive decline and extend
the maintenance of good brain health into old age.
However, all these effects are all broadly described
as a cognitive benefit. Furthermore, there are many
additional subtleties in the analysis of data when pre-
senting a cognitive benefit (see Table 3), and all this
variance is contributing to an absence of consistent
and reliable findings in the reviews presented here.
If the way in which an outcome measure is defined
has considerably variety than there is bound to be
inconsistency in outcomes between studies. More-
over, positive effects with neuroimaging outcomes
(e.g. fMRI, ASL, EEG) are also considered cog-
nitive benefits in studies utilizing these techniques,
however, such measures typically do not, on their
own, include a behavioural outcome (i.e. a perfor-
mance measure from a cognitive task). There are of
course many studies which combine neuroimaging
techniques with behavioural outcomes which provide
important insight into various mechanisms of action.
However, the point is that a change on a neuroimag-
ing outcome is not synonymous with a cognitive
benefit on a behavioural task, and the former can
occur in the absence of the latter. When evaluating
this literature care should be taken when defining
what we mean by a cognitive benefit. Understanding
what type of cognitive benefit we may be expecting
to observe in a given population and experimental
scenario will enhance our understanding of how and
under what conditions polyphenol consumption can
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benefit cognition. Finally, it is also important to reflect
upon what we mean when describing a cognitive
benefit as it has relevance for the application and
translation of experimental research to the public and
policy makers.
CONCLUSIONS
The purpose of this overview was to consider
and summarise the evidence presented in recent
systematic reviews and meta-analyses of the relation-
ship between polyphenol consumption and cognitive
function in humans. All thirteen systematic reviews
offer some degree of support for a benefit of polyphe-
nols for cognition, and on the face of it this sounds
overwhelmingly positive. However, a clear and con-
sistent theme has emerged that these conclusions
are tentative. Indeed, this is reflected when consid-
ering the most robust analyses; three of the five
meta-analyses concluded there was no evidence for
a benefit, and the positive outcomes were small
effects from limited analyses. However, the practi-
cal utility of these meta-analyses is questionable on
the basis that significant methodological heterogene-
ity severely restricted the inclusivity and scope of
the statistical analyses. This limitation is also high-
lighted throughout the systematic reviews, so much
so that conclusions relating to the most efficacious
dose and duration of consumption, the populations
most likely to benefit, or the most sensitive cognitive
domains are not currently possible with any reason-
able degree of reliability or consistency (see Table 2).
There is encouraging evidence that verbal memory
is emerging repeatedly as sensitive to polyphenol
interventions, however, this appears to be driven by
the frequency of assessment rather than by clear
and direct comparisons with other cognitive domains
within or between studies. It is encouraging that risk
of bias was largely deemed as low, and the quality
of studies graded as moderate to high, however, such
analyses with standardised techniques were not rou-
tinely performed. In conclusion, there is evidence that
polyphenols can benefit cognition in humans, but this
evidence is not as convincing as it initially appears.
Future research is required to strengthen the reliabil-
ity of the evidence base, and furthermore, this should
consider the wider impact and interaction between a
variety of direct and indirect mechanisms of action.
This will assist our understanding of the conditions
under which polyphenol induced cognitive benefits
in humans are likely to be observed.
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Polyphenols: food sources and bioavailability. The Ameri-
can Journal of Clinical Nutrition. 2004;79(5):727-47.
[2] Tsao R. Chemistry and biochemistry of dietary polyphenols.
Nutrients. 2010;2(12):1231-46.
[3] Del Rio D, Rodriguez-Mateos A, Spencer JP, Tognolini M,
Borges G, Crozier A. Dietary (poly) phenolics in human
health: structures, bioavailability, and evidence of protec-
tive effects against chronic diseases. Antioxidants & Redox
Signaling. 2013;18(14):1818-92.
[4] Panche AN, Diwan AD, Chandra SR. Flavonoids: an
overview. Journal of Nutritional Science. 2016;5.
[5] Flanagan E, Müller M, Hornberger M, Vauzour D. Impact
of flavonoids on cellular and molecular mechanisms under-
lying age-related cognitive decline and neurodegeneration.
Current Nutrition Reports. 2018;7(2):49-57.
[6] Gildawie KR, Galli RL, Shukitt-Hale B, Carey AN. Protec-
tive effects of foods containing flavonoids on age-related
cognitive decline. Current Nutrition Reports. 2018;7(2):
39-48.
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